Skip to content
Skip to navigation menu
10 Apr 2014
The prospect of four new cancer medicines becoming a reality for patients has taken a huge step forward with the announcement of a £34M investment by a European private biotech company in University research.
ProTide is a platform developed by Professor Chris McGuigan and his team at Cardiff University’s School of Pharmacy and Pharmaceutical Sciences. ProTides are specifically designed to bypass key cancer cell resistance pathways that limit the efficacy of so many of today’s anti-cancer drugs.
Genetic screening could identify children at risk of low IQ development
Cardiff physicists part of international team
Cardiff University’s new course with FutureLearn
Watch more videos
Information on strike action
Annual meeting of Court
New vaccine hope for leading viral cause of birth defects
'War Horse' author tops Cardiff Children’s Literature Festival
Welsh Varsity 2014
This is an externally hosted beta service offered by Google.